The first incretin-based drug approved specifically for weight loss was liraglutide (Saxenda), developed by Novo Nordisk
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
It can also help aid skin burns to heal at a faster rate and increase blood flow to damaged tissues
This is standard for any legitimate GLP-1 telehealth platform
Confidence Patients often ask about safety
Research suggests that Copper Peptide GHK-Cu can: Increase hair follicle size and stimulate growth